GenScript $533M Loss Masks 285% Adjusted Profit Growth

Edgen Stock·Mar 18 2026, 02:54

Share to

Share to

Copy link

Key Takeaways

GenScript Biotech's 2025 earnings present a sharp contrast between accounting losses and operational success. A massive non-cash write-down on an investment pushed the company to a large reported net loss, obscuring record growth in revenue and a near quadrupling of its adjusted net profit, driven by its booming contract development and manufacturing (CDMO) business.

Headline Loss: GenScript reported a $533 million net loss for 2025, a figure driven almost entirely by a non-cash $398 million impairment charge on its investment in associate company Legend Biotech.
Operational Strength: Underlying performance was exceptionally strong, with adjusted net profit increasing 285% to $230 million and total revenue growing 61.4% to $960 million.
Analyst Verdict: Investment bank CICC maintained an 'Outperform' rating, citing core business health, but cut its price target 16.7% to HK$17.90 due to broader market pressures in the Hong Kong pharma sector.

$398M Write-Down Drives $533M Reported Net Loss

GenScript Biotech's 2025 financial results revealed a reported net loss of $533 million, a figure that obscures the company's robust operational health. The loss was primarily caused by a $398 million non-cash impairment charge triggered by a decline in the share price of its associate company, Legend Biotech. This accounting adjustment, along with a $320 million share of Legend's losses, overshadowed a stellar year for GenScript's core businesses. Excluding these items, the company's adjusted net profit soared 285% year-over-year to reach $230 million on record revenue.

CDMO Revenue Explodes 309% to $389M

The company's powerful underlying performance was led by its contract development and manufacturing (CDMO) division, ProBio. The segment's revenue expanded by an explosive 309.1% to $389 million for the year. This growth was fueled by a substantial sub-licensing fee from a deal for an anti-PD-1 single-domain antibody, which analysts see as validation of the commercial value of GenScript's new molecular entity (NME) platform. The company's foundational Life Sciences division also delivered steady results, with revenue climbing 14.8% to $522 million, underscoring sustained demand for its gene-to-protein platform.

CICC Cuts Target 16.7% Despite Strong Fundamentals

On March 18, investment bank CICC reiterated its 'Outperform' rating on GenScript, signaling confidence in the company's operational trajectory and future licensing potential. However, the bank lowered its price target by 16.7% to HK$17.90, attributing the cut to a recent systemic downturn across the Hong Kong pharmaceutical sector rather than company-specific weakness. This dual verdict highlights the central question for investors: whether to focus on the significant accounting loss or the powerful growth demonstrated by the company's core operations, which saw total revenue climb 61.4% to $960 million.